Iwate Medical University
EGFR gene mutations in gastrointestinal tract cancer may limit the value of gefitinib
Published in Lab Law Weekly, June 16th, 2006
"The epidermal growth factor receptor (EGFR) is commonly overexpressed in many human tumors including gastrointestinal tract tumors. Gefitinib is a selective inhibitor of EGFR tyrosine kinase, and blocks several signal transduction pathways including those involved in tumor cell proliferation, angiogenesis and metastasis," scientists writing in the journal Oncology Reports explained.
"Recent mutational and biological studies have suggested that mutations in the tyrosine kinase domain of the EGFR gene are well correlated...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2006-06-16)
More Articles from Lab Law Weekly
- Bipolar Disorder
Study identifies predictors of bipolar disorder risk - Celgene Corporation
Celgene Cellular Therapeutics strengthens intellectual property estate in stem cells - Cumberland Emerging Technologies, Inc.
Tennessee university foundation, technologies initiative sign collaboration agreement - Curon Medical, Inc.
Curon and Novasys announce intellectual property transaction - Dauphin Technology, Inc.
Dauphin Technology Inc. and preferred shareholders settle and dismiss legal actions - ESBATech AG
ESBATech AG announces appointment of James Egan as chief business officer - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
